In line with these findings, treatment of mice with MASLD with a TNFα antibody for one week markedly diminished the increase in peripheral plasma ethanol levels and the loss of ADH activity in liver tissue. This evidence concerns the gene AVP and metabolic dysfunction-associated steatotic liver disease.